CLPA Phase IIa data for CP461

Cell Pathways (CLPA) said that in a Phase IIa trial of patients with chronic lymphocytic leukemia (CLL), 9 of 15 patients receiving 400 mg of CP461 had a reduction from baseline in their absolute lymp...